[Bioundgrd] Fwd: BMES Distinguished Lecture Series May 19th

[Janice Chang]

>>Dear colleagues and friends,
>>
>>The Boston chapter of the Institute of Electrical and Electronics Engineers
>>         (IEEE)-Engineering in Medicine and Biology Society (EMBS)
>>                                  &
>>               the MIT Biomedical Engineering Society (BMES)
>>                           proudly present:
>>
>>        *** The 2003-2004 EMBS-BMES Distinguished Lecture Series ***
>>
>>We invite you to join us for our new monthly lecture series in 
>>which we explore
>>recent developments and stimulating topics in the expanding field 
>>of biomedical
>>engineering.  In the spring, speakers from both academia and 
>>industry will introduce such
>>subjects as genes, genomics, proteomics, and systems biology.
>>
>>Our ninth lecture will be:
>>
>>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>>Moving from Discovery Insight to Market in MA: OR Every Biotech 
>>Blockbuster Needs a Cluster of Supporting Stars
>>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>>
>>Mr. Mark Trusheim
>>Interim President, Massachusetts BioTechnology Council (MBC)
>>Cambridge, MA
>>
>>Wednesday, May 19th, 2004
>>7PM (Refreshments at 6:30PM)
>>MIT Building 66, 25 Ames Street, Room 66-110
>>(For directions to MIT, please visit http://whereis.mit.edu)
>>
>>* This event is free and open to the public.*
>>
>>************************************************************************
>>
>>ABSTRACT:
>>
>>The process from a fundamental scientific insight to a therapeutic 
>>that helps millions of patients around the world is journey filled 
>>with science, applied engineering, financial engineering, politics, 
>>insurers and intrigue. Along the way to becoming an award winning 
>>blockbuster therapy, every biotech product requires a supporting 
>>cast of dozens of stars over at least a decade.
>>
>>SPEAKER BACKGROUND:
>>
>>Mark Trusheim is currently serving as the Interim President of the 
>>Massachusetts Biotechnology Council (MBC) where he has also served 
>>on the Board of Directors for the past 4 years. Mark is the Founder 
>>and was the first President and CEO of Cantata Laboratories. 
>>Cantata markets clinical diagnostics and pharmaceutical biomarker 
>>services based on its biochemical profiling platform. Prior to 
>>Cantata, Mark spent over 10 years at Monsanto, culminating his 
>>career there as Co-President and Chief Operating Officer of Cereon 
>>Genomics, LLC. Located in Cambridge, Massachusetts, Cereon was 
>>created in 1997 by Monsanto to collaborate with Millennium 
>>Pharmaceuticals to improve the world's crops through the use of 
>>Genomics. Prior to his position at Cereon, Mark was responsible for 
>>Monsanto's external genomics relationships and held roles of Vice 
>>President in the Health & Wellness Sector, Marketing Director in 
>>Searle Pharmaceutical and Director in Agriculture Division 
>>Strategy. Prior to entering the life sciences industry, Mark spent 
>>the first half of his career in the computer industry working at 
>>both Wang Laboratories in computer hardware and the start-up Kenan 
>>Systems Corporation in software services. He holds degrees in 
>>Chemistry from Stanford University and Management from MIT.
>>
>>
>>************************************************************************
>>
>>If you have any questions, please do not hesitate to contact us.  We look
>>forward to seeing you!
>>
>>
>>Best Regards,
>>
>>Mandy Yeung					Alexis DeSieno
>>VP of Special Programs			President
>>BMES,MIT Chapter				BMES, MIT Chapter
>>mandyy at mit.edu				alexisd at mit.edu
>>
>>M a n d y  Y e u n g
>>MIT Biology, c/o 05
>>410 memorial drive rm 451-a
>>cambridge, ma 02139
>>tel: (617) 794-1431
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://mailman.mit.edu/pipermail/bioundgrd/attachments/20040511/42d57eeb/attachment.htm